>
Switch to:

Biohaven Pharmaceutical Holding Co Operating Margin %

: -184.96% (As of Jun. 2021)
View and export this data going back to 2017. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Biohaven Pharmaceutical Holding Co's Operating Income for the three months ended in Jun. 2021 was $-171.9 Mil. Biohaven Pharmaceutical Holding Co's Revenue for the three months ended in Jun. 2021 was $92.9 Mil. Therefore, Biohaven Pharmaceutical Holding Co's Operating Margin % for the quarter that ended in Jun. 2021 was -184.96%.

The historical rank and industry rank for Biohaven Pharmaceutical Holding Co's Operating Margin % or its related term are showing as below:

NYSE:BHVN' s Operating Margin % Range Over the Past 10 Years
Min: -1014.33   Med: -1014.33   Max: -391.18
Current: -391.18

-1014.33
-391.18

NYSE:BHVN's Operating Margin % is ranked lower than
99.99% of the 265 Companies
in the Biotechnology industry.

( Industry Median: -295.57 vs. NYSE:BHVN: -391.18 )

Biohaven Pharmaceutical Holding Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Biohaven Pharmaceutical Holding Co's Operating Income for the three months ended in Jun. 2021 was $-171.9 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2021 was $-741.4 Mil.


Biohaven Pharmaceutical Holding Co Operating Margin % Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Operating Margin %
Premium Member Only - - - - -1,014.33

Biohaven Pharmaceutical Holding Co Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Operating Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,655.88 -923.67 -486.13 -537.78 -184.96

Competitive Comparison

For the Biotechnology subindustry, Biohaven Pharmaceutical Holding Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven Pharmaceutical Holding Co Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Biohaven Pharmaceutical Holding Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's Operating Margin % falls into.



Biohaven Pharmaceutical Holding Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Biohaven Pharmaceutical Holding Co's Operating Margin % for the fiscal year that ended in Dec. 2020 is calculated as

Operating Margin %=Operating Income (A: Dec. 2020 ) / Revenue (A: Dec. 2020 )
=-645.388 / 63.627
=-1,014.33 %

Biohaven Pharmaceutical Holding Co's Operating Margin % for the quarter that ended in Jun. 2021 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2021 ) / Revenue (Q: Jun. 2021 )
=-171.891 / 92.933
=-184.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Biohaven Pharmaceutical Holding Co Operating Margin % Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Pharmaceutical Holding Co Business Description

Biohaven Pharmaceutical Holding Co logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Executives
Bailey Gregory director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Gentile Kimberly officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Childs John W director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Berman Robert officer: Special Projects & Med Ovrsght C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Doogan Declan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Stock Elyse officer: Chief Medical Officer 215 CHURCH STREET NEW HAVEN CT 06510
Engelhart James officer: Chief Financial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Tilton John officer: Chief Commercial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Hugin Robert J director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Heffernan Michael Thomas director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Gregory Julia P director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Aguiar Eric director 888 7TH AVENUE 12TH FLOOR NEW YORK NY 10106
Coric Vlad director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Jones William A Jr officer: CCO-Migraine & Common Disease NITROMED, INC. 125 SPRING STREET LEXINGTON MA 02421
Conway Charles officer: Chief Scientific Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510

Biohaven Pharmaceutical Holding Co Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)